⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993425 | 0.48 | MAPK1 (0.43) | — | |
| SCHEMBL57168 | 0.47 | ALDH1A1 (0.47) | — | |
| Water SCHEMBL28206588 | 0.38 | — | — | |
| Water SCHEMBL28491096 | 0.38 | — | — | |
| Water SCHEMBL28277038 | 0.38 | — | — | |
| Water SCHEMBL1498163 | 0.38 | — | — | |
| Water SCHEMBL28811833 | 0.38 | — | — | |
| Water SCHEMBL1325168 | 0.38 | — | — | |
| Water SCHEMBL31186927 | 0.38 | — | — | |
| Water SCHEMBL12002712 | 0.38 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235376-A1 | PROCESS FOR PREPARING 1-(4-CHLOROBENZYL)-1H-IMIDAZOLE-4,5-DICARBOXAMIDE | ZOETIS SERVICES LLC (US) | 2023-12-07 | — | — | WO | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| EP-4399301-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023235376-A1 | PROCESS FOR PREPARING 1-(4-CHLOROBENZYL)-1H-IMIDAZOLE-4,5-DICARBOXAMIDE | ZOETIS SERVICES LLC (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023039076-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-3559008-B1 | COMPOUNDS BASED ON A BORON-GROUP ELEMENT AND THEIR USE IN ELECTROLYTE COMPOSITIONS | SCE FRANCE (FR) | 2022-11-02 | — | — | EP | disclosed |
| EP-3980437-A1 | UNA AMIDITES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2020247818-A1 | UNA AMIDITES AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2019046500-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018176134-A1 | SALTS FOR USE IN ELECTROLYTE COMPOSITIONS OR AS ELECTRODE ADDITIVES | HYDRO-QUéBEC (CA) | 2018-10-04 | — | — | WO | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010006096-A1 | PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-0573218-B1 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO CO (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |